VC Cell Therapy Inc.


News & Media

Notice of Establishment of U.S. Subsidiary

Kobe, Japan, 24 June 2024 : VCCT Inc. (President: Masayo TakahashiTakahashi) announces that it has established a subsidiary in the United States to strengthen its business development with a focus on North America, as follows.

Company name: VCCT USA inc.
Date of establishment: June 24, 2024
Location: 500 La Terraza Blvd Suite 150 Escondido, CA 92025 USA

A word by Masayo Takahashi, President of VCCT Inc.
We believe that the iPS cell-derived retinal pigment epithelium transplant has become an effective treatment and is now ready to be spread worldwide. It has progressed through our unique experience obtained from clinical research since its world-first clinical application in 2014.
As a part of our preparation, we have established a subsidiary in the United States. We will continue to work to bring this treatment to patients in Japan and around the world as soon as